Monographie - Esomeprazole sodium

Son güncelleme :
08/05/2024

Esomeprazole sodium

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Adptor	Meksika
Axagon	İtalya
Axiago	İsveç
Cativa	İsveç
Cronopep	Kolombiya, Peru
Eliprot	Ekvador
Emune	Ekvador
Epral	Şili
Esio	Ekvador
Esmonat	Hindistan, Türkiye
Esoblok	Türkiye
Esofax	Ekvador
Esolium	Peru
Esomep	İsviçre
Esomeprazol	Ekvador, İspanya, Kolombiya, Romanya, Şili
Esomeprazole	Amerika Birleşik Devletleri
Esopral	İsveç, İtalya
Esopran	Peru
Esoton Plus	Peru
Esoz	Hindistan, Kolombiya
Ezole	Peru
Gletop	Venezuela
Inexium	Fransa
Milenium	Ekvador
Nexiam	Belçika, Lüksemburg
Nexium	Almanya, Amerika Birleşik Devletleri, Arjantin, Birleşik Arap Emirlikleri, Büyük Britanya, Ekvador, İrlanda, İspanya, İsveç, İsviçre, İtalya, İzlanda, Kolombiya, Malezya, Meksika, Mısır, Norveç, Portekiz, Romanya, Şili, Suudi Arabistan, Türkiye, Venezuela, Yunanistan
Redica	İsveç
Refexxin	İsveç

Kaynaklar : Esomeprazole sodium

	Tip	Yayın
1506	Dergi	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Dergi	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2262	Dergi	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Dergi	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270	Dergi	Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J. Physical and chemical stability of esomeprazole sodium solutions. Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284	Laboratuar	Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics Astra Zenaca 2007
2311	Dergi	Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. J Clin Pharm Ther 2009 ; 34: 25-31.
3249	Dergi	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Dergi	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratuar	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Dergi	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3429	Dergi	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3827	Afiş	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Afiş	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Afiş	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Dergi	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Dergi	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4055	Dergi	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Dergi	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Dergi	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4465	Dergi	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528	Dergi	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4650	Laboratuar	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4801	Dergi	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales